• Accelero_Spring_2017_1.jpg
  • Accelero_Spring_2017_2.jpg
  • Accelero_Spring_2017_3.jpg
  • Accelero_Spring_2017_4.jpg
  • Accelero_Spring_2017_5.jpg
  • Accelero_Spring_2017_6.jpg
  • Accelero_Spring_2017_7.jpg
  • Accelero_Spring_2017_8.jpg
  • Accelero_Spring_2017_9.jpg

 

Berlin, 04 June 2019

Accelero is pleased to announce that the company participates as a partner organization in the Marie Curie TRAIN-HEART consortium funded by the European Commission.

TRAIN-HEART brings together leading academic teams and (biotech) companies to train the next-generation of innovation-minded researchers who can expand the scientific horizons and accelerate future development of RNA-based therapeutics for the treatment of ischemic heart failure.

TRAIN HEART LogoThe TRAIN-HEART consortium, funded by the European Commission (2019-2023), is made up to train a league of 15 promising fellows that harness novel insights in the pathogenesis of ischemic heart failure, study the therapeutic potential of existing RNA therapeutics and improve its efficacy by the design of novel drug delivery systems. More information can be found on the consortium website www.train-heart.eu.

Accelero Bioanalytics GmbH is a GLP certified contract research service provider for regulatory drug development and maintains genetic engineering (bio)safety level 2 laboratories in compliance with ICH GCP regulations.

Accelero will invite all 15 fellows from 12 institutions located in 6 European countries to a “GLP Summer Seminar 2019” to provide training in the principles of Good Laboratory Practice (GLP).

Furthermore, Accelero will host two fellows from the University of Porto for a secondment period of two months. These fellows will be trained ‘on the job’ by working in the GLP compliant test facility and learn about the development of bioanalytical test methods for the quantification of RNA therapeutics.

Please click hereto download the complete press release.